HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Radzikowska, E. Articles by Bestry, I. Search for Related Content PubMed PubMed Citation Articles by Radzikowska, E. Articles by Bestry, I.

Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer

National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland

CORRESPONDENCE: E. Radzikowska, National Tuberculosis and Lung Diseases Research Institute, 26 Plocka Street, 01–138, Warsaw, Poland. Fax: 48 224312408. E-mail: e.radzikowska@igichp.edu.pl

Keywords: adverse reaction, breast cancer treatment, bronchiolitis obliterans organising pneumonia, organising pneumonia, transtuzumab

Received: April 30, 2002
Accepted August 5, 2002

Abstract

The case of a 49-yr-old female, who developed fever, effort dyspnoea and cough, with patchy migratory bilateral pulmonary infiltrates 6 weeks after starting transtuzumab therapy, following breast-conserving surgery with adjuvant chemoradiotherapy and hormone therapy for breast carcinoma, is reported here.

Chest radiograph and thin section computed tomography demonstrated alveolar opacities with air bronchogram in both lungs. A lung biopsy was performed in a nonirradiated area of the contralateral lung and revealed a typical histological pattern of organising pneumonia (previously known as bronchiolitis obliterans organising pneumonia). Transtuzumab therapy was discontinued and subsequent gradual clinical and radiological improvement was observed. After 3 months, complete resolution of symptoms and radiographical abnormalities were noted.

This is the first case report that suggests that transtuzumab therapy might induce the development of lung infiltrates with the histological appearance of organising pneumonia.

This article has been cited by other articles:

				M. Y. Halyard, T. M. Pisansky, A. C. Dueck, V. Suman, L. Pierce, L. Solin, L. Marks, N. Davidson, S. Martino, P. Kaufman, et al. Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831 J. Clin. Oncol., June 1, 2009; 27(16): 2638 - 2644. [Abstract] [Full Text] [PDF]

				J. P. Lynch III Rare Interstitial Lung Diseases: Pulmonary Langerhans Cell Histiocytosis, Lymphangioleiomyomatosis, and Cryptogenic Organizing Pneumonia ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 585 - 618. [Full Text] [PDF]

				B. Vahid and P. E. Marik Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors* Chest, February 1, 2008; 133(2): 528 - 538. [Abstract] [Full Text] [PDF]

				J-F. Cordier Cryptogenic organising pneumonia. Eur. Respir. J., August 1, 2006; 28(2): 422 - 446. [Abstract] [Full Text] [PDF]

				I. Dimopoulou, A. Bamias, P. Lyberopoulos, and M. A. Dimopoulos Pulmonary toxicity from novel antineoplastic agents Ann. Onc., March 1, 2006; 17(3): 372 - 379. [Abstract] [Full Text] [PDF]